Desonide (Page 2 of 2)
Pediatric Use
Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment.
Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children.
HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
ADVERSE REACTIONS
In controlled clinical trials, the total incidence of adverse reactions associated with the use of Desonide Cream, 0.05% was approximately 1%. These adverse reactions were pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, and burning. Laboratory abnormalities were found in 3% of the patients. These were hyperglycemia (2%) and liver function abnormality (1%).
The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation.
OVERDOSAGE
Topically applied Desonide Cream, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
DOSAGE AND ADMINISTRATION
Desonide Cream, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition.
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary.
Desonide Cream, 0.05% should not be used with occlusive dressings.
HOW SUPPLIED
Desonide Cream, 0.05% is available as follows:
15 g tube (NDC 42254-142-15)
STORAGE
Store at 20-25°C (68-77°F)[see USP Controlled Room Temperature].
MANUFACTURED BY
PERRIGO
BRONX, NY 10457
DISTRUBUTED BY
PERRIGO®
ALLEGAN, MI 49010
Rev. 08/09
1A700 RC J3
REPACKAGED BY:
REBEL DISTRIBUTORS CORP
THOUSAND OAKS, CA 91320
Principal Display Panel
DESONIDE desonide cream | ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
|
Labeler — Rebel Distributors Corp (118802834) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Rebel Distributors Corp | 118802834 | RELABEL, REPACK |
Revised: 01/2012 Rebel Distributors Corp
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.